William Looney
Executive Editor, In Vivo
USA
+41 year(s) experience
In Vivo
In today’s globalized market for medicines, national rules on pricing and access are abundantly shared and more transparent than opaque. In Vivo speaks to the UK branded industry’s negotiator for the latest five-year joint pricing pact with the government, Richard Torbett, who outlines, among other topics, five widely applicable precedents from the talks that can work in “getting to yes” – despite the fractious budgetary climate for health care evident in all major country markets.
Topic Brexit Policy & Regulation
In Vivo
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.
In Vivo
Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.
In Vivo
Former Amgen R&D lead Sean Harper talks exclusively to In Vivo about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.
In Vivo
18 Jan 2021
In Vivo
12 Jan 2021
In Vivo
14 Oct 2020
In Vivo
16 Jul 2020
Generics Bulletin
16 Jun 2020
In Vivo
22 Jan 2020
In Vivo
14 Nov 2019
In Vivo
21 Oct 2019
In Vivo
04 Sep 2019
In Vivo
04 Sep 2019
In Vivo
21 Aug 2019
In Vivo
15 Jul 2019
In Vivo
24 Jun 2019
In Vivo
28 May 2019
In Vivo
13 May 2019